Mendelian Randomization and Cardiovascular Disease - Enabling Expert Readership

Pradeep Natarajan*, Clyde W. Yancy

*Corresponding author for this work

Research output: Contribution to journalComment/debatepeer-review

1 Scopus citations
Original languageEnglish (US)
Pages (from-to)89-90
Number of pages2
JournalJAMA cardiology
Volume9
Issue number1
DOIs
StatePublished - Jan 10 2024

Funding

Conflict of Interest Disclosures: Dr Natarajan reported grants from Allelica, Apple, Amgen, Boston Scientific, Genentech, and Novartis, personal fees from Allelica, Apple, AstraZeneca, Blackstone Life Sciences, Eli Lilly & Co, Foresite Labs, Genentech, GV, HeartFlow, Magnet Biomedicine, Novartis, and Esperion Therapeutics, equity in Preciseli, TenSixteen Bio, and MyOme, and spousal employment at Vertex. Dr Yancy reported spousal employment at Abbott Laboratories and grant support from the National Institutes of Health and PCORI. No other disclosures were reported.

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this